| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Ombuoside targets multiple cellular pathways. It suppresses ROS generation and the mitochondrial apoptotic cascade, protecting cells from oxidative stress-induced damage. The compound's antimicrobial activity is directed against gram-positive and gram-negative bacteria and Candida albicans. Its neuroprotective effects involve protection against apoptosis and oxidative damage.
|
|---|---|
| ln Vitro |
Ombuoside demonstrates in vitro antimicrobial activity against several strains of gram-positive and gram-negative bacteria and the yeast Candida albicans. It has antioxidant effects by scavenging free radicals and ROS. Ombuoside protects hair cells from cisplatin-induced apoptosis by suppressing ROS generation and the mitochondrial apoptotic cascade. It improves chronic stress-induced anxiety in mice.
|
| ln Vivo |
In vivo activity of ombuoside has been demonstrated in animal models. Ombuoside improves chronic stress-induced anxiety in mice, suggesting its potential as a therapeutic approach for the treatment of anxiety disorders. Ombuoside protects hair cells from cisplatin-induced ototoxicity. These findings suggest potential for in vivo efficacy in models of hearing loss and anxiety.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for ombuoside are not extensively documented. Its antioxidant activity can be assessed using DPPH or ABTS radical scavenging assays. The compound's ability to suppress ROS generation can be measured using fluorescent probes such as DCFH-DA in cell cultures. Antimicrobial activity is assessed using standard microbial growth inhibition assays.
|
| Cell Assay |
In vitro cellular assays for ombuoside involve treating auditory cells or other cell types with varying concentrations of the compound. Protection against cisplatin-induced ototoxicity is assessed by measuring cell viability, ROS levels, and mitochondrial membrane potential. Antimicrobial activity is assessed by measuring inhibition of bacterial and fungal growth.
|
| Animal Protocol |
In vivo animal experiments for ombuoside have been conducted in mouse models of chronic stress-induced anxiety. The compound is administered to mice, and anxiety-related behaviors are assessed using behavioral tests. Protection against cisplatin-induced ototoxicity can be evaluated in animal models of hearing loss.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ombuoside are limited. As a flavonol glycoside, its absorption, distribution, metabolism, and excretion properties would influence its bioavailability. The compound is isolated from Gynostemma pentaphyllum. Further pharmacokinetic studies are needed to determine its systemic exposure and elimination pathways.
|
| Toxicity/Toxicokinetics |
Toxicological data for ombuoside are limited. As a natural product-derived compound, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that Ombuoside has been found in Gynostemma pentaphyllum, Gynostemma pentaphyllum, and Sphagnum moss, and relevant data is available for reference.
Ombuoside (CAS#: 20188-85-6) has the molecular formula C28H32O16 and a molecular weight of 624.54. It is a flavonol glycoside isolated from Gynostemma pentaphyllum. Ombuoside has antimicrobial activity against gram-positive and gram-negative bacteria and Candida albicans. It has antioxidant effects and protects against cisplatin-induced ototoxicity. It is for research use only. |
| Molecular Formula |
C29H34O16
|
|---|---|
| Molecular Weight |
638.57
|
| Exact Mass |
638.184
|
| CAS # |
20188-85-6
|
| PubChem CID |
10100634
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
947.6±65.0 °C at 760 mmHg
|
| Flash Point |
308.6±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
2.17
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
45
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)OC)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O
|
| InChi Key |
VVSFMIXQNYRGMG-BDAFLREQSA-N
|
| InChi Code |
InChI=1S/C29H34O16/c1-10-19(32)22(35)24(37)28(42-10)41-9-17-20(33)23(36)25(38)29(44-17)45-27-21(34)18-14(31)7-12(39-2)8-16(18)43-26(27)11-4-5-15(40-3)13(30)6-11/h4-8,10,17,19-20,22-25,28-33,35-38H,9H2,1-3H3/t10-,17+,19-,20+,22+,23-,24+,25+,28+,29-/m0/s1
|
| Chemical Name |
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (78.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5660 mL | 7.8300 mL | 15.6600 mL | |
| 5 mM | 0.3132 mL | 1.5660 mL | 3.1320 mL | |
| 10 mM | 0.1566 mL | 0.7830 mL | 1.5660 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
